


LITERATURA

- Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*. 2009;120:1640-1645. Available from DOI: 10.1161/CIRCULATIONAHA.109.192644.
- Definice metabolického syndromu podle Českého institutu metabolického syndromu, o.p.s. Dostupné z: <http://www.cims-ops.cz/cz/uvod>. Cit. 24.1. 2010.
- <https://www.svl.cz/files/files/Doporučene-postupy/2023/DP-Metabolicky-syndrom.pdf>.
- Cífková R, Bruthans J, Adámková V, et al. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006–2009. *Studia Czech postMONICA*. *Cor Vasa*. 2011;53:220-229. Available from DOI: 10.33678/cor.2011.050.
- Yanai H, Tomono Y, Ito K, et al. The underlying mechanisms for development of hypertension in the metabolic syndrome. *Nutr J*. 2008;7:10. Available from 10.1186/1475-2891-7-10.
- Rosolová H. Sympatický nervový systém a kardiovaskulární riziko. Praha: Maxdorf, 2000.
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *Journal of Hypertension*. 2023;41(12):1874-2071. Available from DOI: 10.1097/HJH.0000000000003480.
- Widimský J, Filipovský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze. Doporučení České společnosti pro hypertenzi 2022. *Hypertenze a kardiovaskulární prevence*. 2022;12(2)Suppl:1-23.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2018;138:e426-e483. Available from DOI: doi.org/10.1161/CIR.0000000000000597.
- Suvila K, McCabe EL, Lehtonen A, et al. Early Onset Hypertension Is Associated With Hypertensive End-Organ Damage Already by MidLife. *Hypertension*. 2019;74(2):305-312. Available from DOI: 10.1161/HYPERTENSIONAHA.119.13069.
- Suvila K, Lima JAC, Yano Y, et al. Early-but Not Late –Onset Hypertension Is Related to Mid-life Cognitive Function. *Hypertension*. 2021;77(3):972-979. Available from DOI: 10.1161/HYPERTENSIONAHA.120.16556.
- Lee CJ, Hwang J, Kang CY, et al. Protective effect of controlled blood pressure on risk of dementia in low-risk, grade 1 hypertension. *J Hypertens*. 2021;39(8):1662-1669. Available from DOI: 10.1097/HJH.0000000000002820.
- Czernichow S, Ninomiya T, Huxley R et al. Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial. *Hypertension*. 2010;55:1193-1198. Available from DOI: 10.1161/HYPERTENSIONAHA.109.140624.
- Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. *Diabetes Care*. 2006;29:2592-2597. Available from DOI: 10.2337/dc06-1373.
- Agarwal R, Anker SD, Bakris G, et al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. *Nephrol Dial Transplant*. 2022;37(6):1014-1023. Available from DOI: 10.1093/ndt/gfaa294.
- Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2016;375(4):311-22. Available from DOI: 10.1056/NEJMoa1603827.
- Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med*. 2015;373(22):2117-2128. Available from DOI: 10.1056/NEJMoa1504720.
- Neeland IJ, McGuire DK, Chilton R, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. *Diab Vasc Dis Res*. 2016;13(2):119-126. Available from DOI: 10.1177/1479164115616901.
- Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Diabetes Endocrinol*. 2016;4(3):211-220. Available from DOI: 10.1016/S2213-8587(15)00417-9.
- Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2016;375(19):1834-1844. Available from DOI: 10.1056/NEJMoa1607141.
- Group SR, Wright JT, Jr., Williamson JD, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med*. 2015;373:2103-2116. Available from DOI: 10.1056/NEJMoa1511939.

Vyberte si publikace z různých oblastí medicíny v našem e-shopu

Prolistujte si ukázky z knih →



Knihy oceňované odbornými společnostmi




Cena děkana LF UP za významnou publikační činnost za rok 2013 v kategorii monografie a 2. místo v literární soutěži České internistické společnosti.



Cena České onkologické společnosti za nejlepší knižní publikaci 2017 a také 1. místo v soutěži České urologické společnosti o nejlepší vědeckou publikaci za rok 2017 v kategorii „Monografie nebo postgraduální učební text“.

Cena České urologické společnosti ČLS JEP za rok 2022



Publikace ke stažení zdarma

E-verze časopisů za zvýhodněnou cenu

